S&P 500   3,955.16 (-0.21%)
DOW   33,686.11 (-0.28%)
QQQ   283.75 (-0.04%)
AAPL   142.11 (-0.38%)
MSFT   245.96 (-0.58%)
META   115.51 (+0.16%)
GOOGL   94.00 (+0.31%)
AMZN   89.88 (-0.52%)
TSLA   178.79 (+3.08%)
NVDA   173.30 (+0.94%)
NIO   13.15 (-1.94%)
BABA   93.20 (-1.03%)
AMD   69.73 (-1.05%)
T   19.13 (+0.05%)
MU   55.23 (+0.05%)
CGC   3.03 (-1.94%)
F   13.21 (+0.69%)
GE   83.06 (-0.68%)
DIS   93.28 (+0.79%)
AMC   6.02 (-0.82%)
PYPL   74.37 (+0.20%)
PFE   52.57 (+1.53%)
NFLX   322.10 (+3.82%)
S&P 500   3,955.16 (-0.21%)
DOW   33,686.11 (-0.28%)
QQQ   283.75 (-0.04%)
AAPL   142.11 (-0.38%)
MSFT   245.96 (-0.58%)
META   115.51 (+0.16%)
GOOGL   94.00 (+0.31%)
AMZN   89.88 (-0.52%)
TSLA   178.79 (+3.08%)
NVDA   173.30 (+0.94%)
NIO   13.15 (-1.94%)
BABA   93.20 (-1.03%)
AMD   69.73 (-1.05%)
T   19.13 (+0.05%)
MU   55.23 (+0.05%)
CGC   3.03 (-1.94%)
F   13.21 (+0.69%)
GE   83.06 (-0.68%)
DIS   93.28 (+0.79%)
AMC   6.02 (-0.82%)
PYPL   74.37 (+0.20%)
PFE   52.57 (+1.53%)
NFLX   322.10 (+3.82%)
S&P 500   3,955.16 (-0.21%)
DOW   33,686.11 (-0.28%)
QQQ   283.75 (-0.04%)
AAPL   142.11 (-0.38%)
MSFT   245.96 (-0.58%)
META   115.51 (+0.16%)
GOOGL   94.00 (+0.31%)
AMZN   89.88 (-0.52%)
TSLA   178.79 (+3.08%)
NVDA   173.30 (+0.94%)
NIO   13.15 (-1.94%)
BABA   93.20 (-1.03%)
AMD   69.73 (-1.05%)
T   19.13 (+0.05%)
MU   55.23 (+0.05%)
CGC   3.03 (-1.94%)
F   13.21 (+0.69%)
GE   83.06 (-0.68%)
DIS   93.28 (+0.79%)
AMC   6.02 (-0.82%)
PYPL   74.37 (+0.20%)
PFE   52.57 (+1.53%)
NFLX   322.10 (+3.82%)
S&P 500   3,955.16 (-0.21%)
DOW   33,686.11 (-0.28%)
QQQ   283.75 (-0.04%)
AAPL   142.11 (-0.38%)
MSFT   245.96 (-0.58%)
META   115.51 (+0.16%)
GOOGL   94.00 (+0.31%)
AMZN   89.88 (-0.52%)
TSLA   178.79 (+3.08%)
NVDA   173.30 (+0.94%)
NIO   13.15 (-1.94%)
BABA   93.20 (-1.03%)
AMD   69.73 (-1.05%)
T   19.13 (+0.05%)
MU   55.23 (+0.05%)
CGC   3.03 (-1.94%)
F   13.21 (+0.69%)
GE   83.06 (-0.68%)
DIS   93.28 (+0.79%)
AMC   6.02 (-0.82%)
PYPL   74.37 (+0.20%)
PFE   52.57 (+1.53%)
NFLX   322.10 (+3.82%)
NASDAQ:ARDX

Ardelyx - ARDX Stock Forecast, Price & News

$1.81
-0.01 (-0.55%)
(As of 12/9/2022 09:46 AM ET)
Add
Compare
Today's Range
$1.77
$1.83
50-Day Range
$1.19
$2.08
52-Week Range
$0.49
$2.19
Volume
7,268 shs
Average Volume
18.78 million shs
Market Capitalization
$339.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Ardelyx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
174.7% Upside
$5.00 Price Target
Short Interest
Healthy
4.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$150,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

335th out of 1,022 stocks

Pharmaceutical Preparations Industry

138th out of 499 stocks

ARDX stock logo

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Stock News Headlines

Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Why Is Ardelyx (ARDX) Stock Up 38% Today?
Ardelyx Third Quarter 2022 Earnings: Beats Expectations
Ardelyx (ARDX) Reports Q3 Loss, Tops Revenue Estimates
Ardelyx (NASDAQ: ARDX)
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Company Calendar

Last Earnings
11/12/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
86
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+176.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-158,160,000.00
Net Margins
-1,266.91%
Pretax Margin
-1,266.82%

Debt

Sales & Book Value

Annual Sales
$10.10 million
Book Value
$0.73 per share

Miscellaneous

Free Float
176,212,000
Market Cap
$339.30 million
Optionable
Optionable
Beta
1.47

Key Executives

  • Mr. Michael G. RaabMr. Michael G. Raab (Age 57)
    Pres, CEO & Director
    Comp: $1.04M
  • Mr. Justin A. Renz CPA (Age 50)
    M.S.T., MBA, MST, CFO & Treasurer
    Comp: $623.7k
  • Ms. Elizabeth A. GrammerMs. Elizabeth A. Grammer (Age 58)
    Chief Legal & Admin. Officer and Sec.
    Comp: $623.7k
  • Mr. David P. Rosenbaum (Age 61)
    Chief Devel. Officer
    Comp: $645.4k
  • Mr. Robert C. BlanksMr. Robert C. Blanks (Age 62)
    Chief Regulatory Affairs & Quality Assurance Officer
    Comp: $590.8k
  • Mr. Robert Felsch
    Sr. VP of Fin. & Chief Accounting Officer
  • Ms. Kimia Keshtbod
    Mang. of Corp. Communications & Investor Relations
  • Ms. Karen Harrigan
    Sr. Director Market Devel.
  • Dan Pavicich
    Sr. Director of Market Devel.
  • Ms. Susan Rodriguez (Age 58)
    Chief Commercial Officer













ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price forecast for 2023?

4 analysts have issued 1-year price targets for Ardelyx's stock. Their ARDX share price forecasts range from $1.00 to $10.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 174.7% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2022?

Ardelyx's stock was trading at $1.10 at the beginning of the year. Since then, ARDX stock has increased by 65.5% and is now trading at $1.82.
View the best growth stocks for 2022 here
.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in November. As of November 15th, there was short interest totaling 8,590,000 shares, an increase of 17.0% from the October 31st total of 7,340,000 shares. Based on an average trading volume of 8,020,000 shares, the days-to-cover ratio is currently 1.1 days.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.07. The biopharmaceutical company had revenue of $1.17 million for the quarter, compared to analyst estimates of $0.85 million. Ardelyx had a negative trailing twelve-month return on equity of 171.18% and a negative net margin of 1,266.91%.

What other stocks do shareholders of Ardelyx own?
What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.06%), Point72 Asset Management L.P. (0.99%), BlackRock Inc. (0.81%), Prosight Management LP (0.60%), Boothbay Fund Management LLC (0.25%) and State Street Corp (0.22%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $1.82.

How much money does Ardelyx make?

Ardelyx (NASDAQ:ARDX) has a market capitalization of $341.18 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158,160,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 12/9/2022 by MarketBeat.com Staff